A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.
(2006) Cancer Immunology, Immunotherapy : other biological response modifications — Vol. 55, n° 6, p. 644-652 (2006)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 355.68 KB
Details
- Authors
- Abstract
- Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.
- Affiliations
Citations
Sun, Z., LETHE, B., Zhang, Y., Russo, V., Colau, D., Stroobant, V., Boon-Falleur, T., & van der Bruggen, P. (2006). A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunology, Immunotherapy : other biological response modifications, 55(6), 644-652. https://doi.org/10.1007/s00262-005-0066-x (Original work published 2006)